Company / Accounts Receivable
Zomedica Corp. Accounts Receivable History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$3.0M
FY2025
5-year range
$596.0K / $3.0M
FY2022-FY2025
Trend
+24.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 3 consecutive years, from $596,000 in FY2022 to $3M in FY2025.
Based on SEC 10-K filings.
$3M in FY2025 with a 3-year CAGR of +71.6%.
Improved from $1M to $3M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +71.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Zomedica Corp.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +71.6%, indicating consistent growth.
- In FY2025, accounts receivable increased 24.3% year-over-year.
Company context
Key Data Points
- Altman Z-Score 0.66 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | +24.3% |
| FY2024 | $2.4M | +102.4% |
| FY2023 | $1.2M | +100.8% |
| FY2022 | $596.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026